International Clinical Trial: A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (NCT07361497) titled 'A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)' on Jan. 21.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Bristol-Myers Squibb

Condition: Non-small Cell Lung Cancer (NSCLC)

Intervention: Drug: Pumitamig

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: April 9, 2026

Target Sample Size: 850

Countries of Recr...